News & Press Releases

Integrity Applications Names Prof. Lutz Heinemann to Advisory Board

February 27th, 2015

Integrity Applications Names Prof. Lutz Heinemann to Advisory Board


Preeminent Expert In Diabetes Study Will Head New Advisory Board


ASHKELON, Israel, February 26, 2015 /PRNewswire/ — Integrity Applications, Inc. (OTCQB: IGAP) (the “Company” or “Integrity”), developer of the GlucoTrack® model DF-F, a noninvasive   device that tracks blood glucose levels, announced today that Dr. Lutz Heinemann, Ph.D., will head its new scientific advisory board that is expected to include key opinion leaders in the field of Diabetes research, monitoring and treatment.

Prof. Dr. Lutz Heinemann, Ph.D has been Chief Executive Officer and Head, Business Development of Profil Institute for Metabolic Research, Ltd., an internationally recognized research institute for clinical studies in the area of diabetes mellitus headquartered in Neuss, Germany, from 1999 until 2009. Dr. Heinemann served as Director of Scientific Services at Profil Institute for Clinical Research, Inc. and serves as its Senior Scientific Consultant. Dr. Heinemann has performed clinical studies for major suppliers of insulin products in the world. Dr. Heinemann is an International Authority on insulin absorption and utilization in the human body. His glucose clamp studies have become the standard in the scientific community for assessing the pharmacodynamic and pharmacokinetic profile of insulin formulations. He serves on several advisory boards and scientific study groups within the pharmaceuticals industry. He is Managing Editor of the Journal of Diabetes Science & Technology and is a Member of the Editorial Board of Diabetes Technology & Therapeutics. In addition, he has published numerous articles on the treatment of diabetes. He earned Engineering Degree from Polytechnic College in Dusseldorf and Degree in Biology and Doctorate in Natural Sciences from University of Düsseldorf.


“I am pleased to lead Integrity Applications’ advisory board,” said Dr. Lutz Heinemann. “Diabetes management is crucial and I trust that Integrity Applications’ GlucoTrack fulfills an unmet need for noninvasive glucose monitoring. I look forward to assisting with rounding out this advisory board with other members who are distinguished in the field of Diabetes research, monitoring and treatment”


“We are honored to have Dr. Lutz Heinemann as head of our advisory board,” said Avner Gal, President and CEO of Integrity Applications, “Dr. Heinemann is recognized as the preeminent expert in the field of diabetes and we believe that he will be an invaluable resource to us as we strive to make diabetes monitoring and management more efficient and less cumbersome.”



About GlucoTrack

GlucoTrack® monitors blood glucose levels without the need to draw blood. GlucoTrack® features a small sensor that clips to the earlobe and tracks the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on a small handheld device, the size of a mobile phone. The derived blood glucose measurement is also announced verbally, making it suitable for the elderly and vision-impaired diabetes patients. The Company has obtained a CE Mark approval for its GlucoTrack® Model DF-F in Europe (June 2013) and final CE Mark approval in March 2014, and intends to seek Food and Drug Administration approval for GlucoTrack® Model DF-F in the United States.


About Integrity Applications, Inc.

Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack® model DF-F noninvasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost and difficulty or discomfort of conventional (invasive) spot finger stick devices. Integrity Applications operates primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect,” and “will,” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); the ability of Integrity Applications to successfully commercialize the GlucoTrack® model DF-F; the ability of the GlucoTrack® model DF-F to achieve acceptable pricing, adequate third party reimbursement or market acceptance; the ability of Integrity Applications to manage its growth and the expansion of its operations to include commercialization activities; risks relating to the use of third party manufacturers; risks relating to the development of Integrity Applications’ sales, marketing and distribution capability, either on its own or through collaborations with marketing partners; the possibility that the distributors will not satisfy their minimum purchase commitments under their distribution agreements; risks relating to the receipt (and timing) of foreign regulatory approvals; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013.


Eran Hertz, CFO

Integrity Applications
+972 (8) 675-7878 ext. #3

Back to all news & press releases

Sign up to our newsletter
To receive occasional news updates

LinkedIn Facebook Twitter